Abstracts

Poster-Disease-modifying Therapy

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More

Poster-Disease-modifying Therapy

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More

Poster-Disease-modifying Therapy

Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)

Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....

Read More

Poster-Complementary and Alternative Therapies

Mindfulness Based Art Therapy to Improve Symptoms Among Adults with Multiple Sclerosis

Background: Multiple sclerosis (MS) MS affects nearly one million people in the United States and more than two million worldwide. Symptoms...

Read More

Poster-Case Reports / Case Series

Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate

Background: The use of disease modifying treatments (DMTs) in multiple sclerosis (MS) has been well studied and has shown to reduce...

Read More

Poster-Case Reports / Case Series

Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence?

Background: MOG antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder characterized by IgG antibodies against...

Read More

Poster-Case Reports / Case Series

Identifying and Treating Steroid-Induced Psychosis in MS Patients Using Quetiapine

Background: High-dose corticosteroids (CS) (1g IV methylprednisolone or 1250 mg oral prednisone for 3-5 days) is the most common treatment...

Read More

Poster-Case Reports / Case Series

Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Background: Bilateral involvement and severe visual impairment can occur in the acute phase of pediatric myelin oligodendrocyte...

Read More

Poster-Case Reports / Case Series

Treatment Resistant Tinea Corporis in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: Tinea corporis is a fungal infection of the skin excluding the face, hands, feet, scalp, nail, or groin. It mostly affects the...

Read More

Poster-Complementary and Alternative Therapies

Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS

Background: MS care provided in a comprehensive MS center improves outcomes. Well-established MS centers struggle to include complementary...

Read More